APOL2

Summary

APOL2 (apolipoprotein L2, HGNC:619) is a protein-coding gene on chromosome 22q12.3, encoding Apolipoprotein L2 (Q9BQE5). May affect the movement of lipids in the cytoplasm or allow the binding of lipids to organelles.

This gene is a member of the apolipoprotein L gene family. The encoded protein is found in the cytoplasm, where it may affect the movement of lipids or allow the binding of lipids to organelles. Two transcript variants encoding the same protein have been found for this gene.

Source: NCBI Gene 23780 — RefSeq curated summary.

At a glance

• Gene–disease (curated): schizophrenia (No Known Disease Relationship, GenCC)
• GWAS associations: 2
• Clinical variants (ClinVar): 97 total
• Phenotypes (HPO): 7
• MANE Select transcript: NM_030882

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:619
Approved symbol	APOL2
Name	apolipoprotein L2
Location	22q12.3
Locus type	gene with protein product
Status	Approved
Aliases	APOL-II
Ensembl gene	ENSG00000128335
Ensembl biotype	protein_coding
OMIM	607252
Entrez	23780

Gene structure

Transcript identifiers

Ensembl transcripts: 16 — 12 protein_coding, 4 protein_coding_CDS_not_defined

ENST00000249066, ENST00000358502, ENST00000451256, ENST00000454728, ENST00000473549, ENST00000476579, ENST00000484830, ENST00000489186, ENST00000529194, ENST00000866480, ENST00000866481, ENST00000866482, ENST00000866483, ENST00000946286, ENST00000946287, ENST00000946288

RefSeq mRNA: 2 — MANE Select: NM_030882 NM_030882, NM_145637

CCDS: CCDS43014

Canonical transcript exons

ENST00000358502 — 5 exons

Exon	Start	End
ENSE00001773877	36231340	36231466
ENSE00002189250	36239441	36239527
ENSE00003524504	36233153	36233241
ENSE00003524514	36233402	36233455
ENSE00003712559	36226209	36228280

Expression profiles

Bgee: expression breadth ubiquitous, 282 present calls, max score 99.57.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 23.6669 / max 685.6169, expressed in 1788 samples.

FANTOM5 promoters (3 alternative TSS)

Promoter ID	TPM avg	Samples expressed
193875	18.1791	1683
193876	5.1568	1616
193877	0.3310	128

Top tissues by expression

290 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
tendon of biceps brachii	UBERON:0008188	99.57	gold quality
granulocyte	CL:0000094	96.69	gold quality
apex of heart	UBERON:0002098	95.67	gold quality
gall bladder	UBERON:0002110	95.50	gold quality
adenohypophysis	UBERON:0002196	94.72	gold quality
medial globus pallidus	UBERON:0002477	94.70	gold quality
blood	UBERON:0000178	94.34	gold quality
cerebellar cortex	UBERON:0002129	94.32	gold quality
cerebellar hemisphere	UBERON:0002245	94.32	gold quality
monocyte	CL:0000576	94.22	gold quality
right frontal lobe	UBERON:0002810	94.14	gold quality
right hemisphere of cerebellum	UBERON:0014890	94.07	gold quality
tibial nerve	UBERON:0001323	93.82	gold quality
pituitary gland	UBERON:0000007	93.76	gold quality
body of uterus	UBERON:0009853	93.74	gold quality
leukocyte	CL:0000738	93.58	gold quality
cerebellum	UBERON:0002037	93.58	gold quality
smooth muscle tissue	UBERON:0001135	93.57	gold quality
upper lobe of left lung	UBERON:0008952	93.54	gold quality
lymph node	UBERON:0000029	93.52	gold quality
right lobe of liver	UBERON:0001114	93.51	gold quality
mononuclear cell	CL:0000842	93.45	gold quality
spleen	UBERON:0002106	93.34	gold quality
omental fat pad	UBERON:0010414	93.33	gold quality
peritoneum	UBERON:0002358	93.32	gold quality
vena cava	UBERON:0004087	93.19	gold quality
globus pallidus	UBERON:0001875	93.04	gold quality
pericardium	UBERON:0002407	93.00	gold quality
left uterine tube	UBERON:0001303	92.91	gold quality
cingulate cortex	UBERON:0003027	92.85	gold quality

Single-cell (SCXA)

Detected in 6 experiment(s), a significant marker in 4.

Experiment	Marker?	Max mean expression
E-MTAB-7052	yes	815.28
E-GEOD-81608	yes	16.61
E-ANND-3	yes	11.21
E-MTAB-5061	yes	8.88
E-MTAB-7303	no	281.80
E-MTAB-7249	no	78.58

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

36 targeting APOL2, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-3613-3P	100.00	76.36	7965
HSA-MIR-3925-3P	100.00	69.95	1237
HSA-MIR-371B-5P	99.99	75.34	4759
HSA-MIR-373-5P	99.98	75.36	4753
HSA-MIR-616-5P	99.98	75.58	4775
HSA-MIR-6783-3P	99.89	67.92	2059
HSA-MIR-1343-3P	99.89	66.78	1815
HSA-MIR-136-5P	99.50	67.26	1153
HSA-MIR-20A-3P	99.44	69.10	1575
HSA-MIR-548AV-3P	99.43	68.50	1721
HSA-MIR-584-3P	99.35	67.69	1082
HSA-MIR-3064-5P	99.26	66.13	1497
HSA-MIR-3085-3P	99.26	66.16	1490
HSA-MIR-6504-5P	99.26	65.95	1487
HSA-MIR-5690	99.25	67.58	1012
HSA-MIR-3199	99.17	65.19	696
HSA-MIR-8052	99.17	65.01	719
HSA-MIR-6749-3P	99.00	65.73	1443
HSA-MIR-1207-3P	98.99	66.22	1532
HSA-MIR-939-3P	98.97	65.07	2347
HSA-MIR-6737-3P	98.95	68.56	1577
HSA-MIR-7157-3P	98.95	68.70	1582
HSA-MIR-330-5P	98.73	67.63	1788
HSA-MIR-4290	98.51	65.17	907
HSA-MIR-6764-3P	98.44	67.64	1153
HSA-MIR-6824-3P	98.44	67.62	1154
HSA-MIR-326	98.25	66.44	1565
HSA-MIR-4518	98.12	66.82	1030
HSA-MIR-1266-5P	97.71	66.92	1052
HSA-MIR-4288	97.11	67.23	1636

Literature-anchored findings (GeneRIF, showing 6)

• APOL2 has been found only in humans and African green monkeys (PMID:11944986)
• An association of APOL1, 2 and 4 with schizophrenia was establised. (PMID:18632255)
• Results reveal a novel function for ApoL2 in conferring anti-apoptotic ability of human bronchial epithelium to the cytotoxic effects of IFN-gamma, in maintaining airway epithelial layer integrity. (PMID:20665705)
• Apolipoprotein L2 contains a BH3-like domain but it does not behave as a BH3-only protein. (PMID:24901046)
• Epigenetic aging is accelerated in alcohol use disorder and regulated by genetic variation in APOL2. (PMID:31466081)
• Structures of the ApoL1 and ApoL2 N-terminal domains reveal a non-classical four-helix bundle motif. (PMID:34316015)

Cross-species orthologs

13 orthologs

Organism	Symbol	Gene ID
danio_rerio	apol	ENSDARG00000073718
mus_musculus	Apol10b	ENSMUSG00000050014
mus_musculus	Apol10a	ENSMUSG00000050982
mus_musculus	Apol9a	ENSMUSG00000057346
mus_musculus	Apol9b	ENSMUSG00000068246
mus_musculus	Apol11a	ENSMUSG00000091650
mus_musculus	Apol11b	ENSMUSG00000091694
rattus_norvegicus	Apol9a	ENSRNOG00000023410
rattus_norvegicus	Apol3l1	ENSRNOG00000042771
rattus_norvegicus	LOC120093819	ENSRNOG00000069032
rattus_norvegicus		ENSRNOG00000081988
caenorhabditis_elegans		WBGENE00017219
caenorhabditis_elegans		WBGENE00017220

Paralogs (6): APOL4 (ENSG00000100336), APOL1 (ENSG00000100342), APOL3 (ENSG00000128284), APOL5 (ENSG00000128313), APOLD1 (ENSG00000178878), APOL6 (ENSG00000221963)

Protein

Protein identifiers

Apolipoprotein L2 — Q9BQE5 (reviewed: Q9BQE5)

Alternative names: Apolipoprotein L-II

All UniProt accessions (4): Q9BQE5, B0QYK8, E9PM95, J3KQL8

UniProt curated annotations — full annotation on UniProt →

Function. May affect the movement of lipids in the cytoplasm or allow the binding of lipids to organelles.

Subcellular location. Cytoplasm.

Tissue specificity. Widely expressed; the highest levels are found in lung, thymus, pancreas, placenta, adult brain and prostate; also detected in spleen, liver, kidney, colon, small intestine, uterus, spinal cord, adrenal gland, salivary gland, trachea, mammary gland, skeletal muscle, testis and fetal brain and liver.

Similarity. Belongs to the apolipoprotein L family.

RefSeq proteins (2): NP_112092, NP_663612 (=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR008405	ApoL	Family

Pfam: PF05461

UniProt features (10 total): helix 4, modified residue 2, sequence variant 2, chain 1, sequence conflict 1

Structure

Experimental structures (PDB)

1 structures.

PDB	Method	Resolution (Å)
7LF8	X-RAY DIFFRACTION	2.15

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q9BQE5-F1	54.04	0.00

Antibody-complex structures (SAbDab): 1 — 7LF8

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (2): 1, 250

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 148 (showing top): GOBP_INFLAMMATORY_RESPONSE, GOBP_LIPOPROTEIN_METABOLIC_PROCESS, BLALOCK_ALZHEIMERS_DISEASE_UP, GOBP_LIPID_METABOLIC_PROCESS, GOBP_MULTI_MULTICELLULAR_ORGANISM_PROCESS, GOBP_MATERNAL_PROCESS_INVOLVED_IN_FEMALE_PREGNANCY, GOMF_SIGNALING_RECEPTOR_BINDING, GOBP_LIPID_LOCALIZATION, GOBP_STEROID_METABOLIC_PROCESS, GOBP_ACUTE_PHASE_RESPONSE, ACEVEDO_LIVER_CANCER_WITH_H3K27ME3_DN, GOBP_ALCOHOL_METABOLIC_PROCESS, GOCC_NUCLEAR_OUTER_MEMBRANE_ENDOPLASMIC_RETICULUM_MEMBRANE_NETWORK, GOCC_ORGANELLE_SUBCOMPARTMENT, GOMF_PROTEIN_LIPID_COMPLEX_BINDING

GO Biological Process (6): lipid metabolic process (GO:0006629), lipid transport (GO:0006869), acute-phase response (GO:0006953), cholesterol metabolic process (GO:0008203), lipoprotein metabolic process (GO:0042157), maternal process involved in female pregnancy (GO:0060135)

GO Molecular Function (4): signaling receptor binding (GO:0005102), high-density lipoprotein particle binding (GO:0008035), lipid binding (GO:0008289), protein binding (GO:0005515)

GO Cellular Component (4): extracellular region (GO:0005576), endoplasmic reticulum membrane (GO:0005789), membrane (GO:0016020), cytoplasm (GO:0005737)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cellular anatomical structure	3
binding	2
primary metabolic process	1
transport	1
lipid localization	1
acute inflammatory response	1
sterol metabolic process	1
secondary alcohol metabolic process	1
protein metabolic process	1
female pregnancy	1
multicellular organismal reproductive process	1
protein binding	1
lipoprotein particle binding	1
organelle membrane	1
nuclear outer membrane-endoplasmic reticulum membrane network	1
endoplasmic reticulum subcompartment	1
intracellular anatomical structure	1

Protein interactions and networks

STRING

652 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
APOL2	COMT	P21964	671
APOL2	CGB5	P01233	524
APOL2	SNRPB2	P08579	512
APOL2	PRODH	O43272	490
APOL2	CHRM4	P08173	490
APOL2	PRODH	O43272	467
APOL2	TNFRSF10A	O00220	464
APOL2	PLAAT2	Q9NWW9	456
APOL2	CGB5	P01233	447
APOL2	PDE4B	Q07343	423
APOL2	OR2AK2	Q8NG84	414
APOL2	MYH9	P35579	400
APOL2	PXT1	Q8NFP0	400
APOL2	P2RY11	Q96G91	397
APOL2	APOO	Q9BUR5	392

IntAct

158 interactions, top by confidence:

A	B	Type	Score
GBP5	GBP1	psi-mi:“MI:0914”(association)	0.720
CFTR	ESYT2	psi-mi:“MI:0914”(association)	0.710
APOL2	TMEM179B	psi-mi:“MI:0915”(physical association)	0.560
APOL2	ERGIC3	psi-mi:“MI:0915”(physical association)	0.560
APOL2	MFF	psi-mi:“MI:0915”(physical association)	0.560
STX2	APOL2	psi-mi:“MI:0915”(physical association)	0.560
STX1A	APOL2	psi-mi:“MI:0915”(physical association)	0.560
ITGB2	APOL2	psi-mi:“MI:0915”(physical association)	0.560
TMED8	APOL2	psi-mi:“MI:0915”(physical association)	0.560
MARCHF3	APOL2	psi-mi:“MI:0915”(physical association)	0.560
APOL2	SLC26A6	psi-mi:“MI:0915”(physical association)	0.560
APOL2	SIT1	psi-mi:“MI:0915”(physical association)	0.560
APOC4	APOL2	psi-mi:“MI:0915”(physical association)	0.560
SLC18A1	APOL2	psi-mi:“MI:0915”(physical association)	0.560
GET1	APOL2	psi-mi:“MI:0915”(physical association)	0.560
APOL2	USE1	psi-mi:“MI:0915”(physical association)	0.560
APOL2	AIG1	psi-mi:“MI:0915”(physical association)	0.560
PANX1	APOL2	psi-mi:“MI:0915”(physical association)	0.560
APOL2	TMEM60	psi-mi:“MI:0915”(physical association)	0.560
TMEM45B	APOL2	psi-mi:“MI:0915”(physical association)	0.560
CYBC1	APOL2	psi-mi:“MI:0915”(physical association)	0.560

BioGRID (146): APOL2 (Affinity Capture-MS), APOL2 (Affinity Capture-MS), APOL2 (Affinity Capture-MS), UBB (Affinity Capture-MS), APOL2 (Affinity Capture-MS), APOL2 (Affinity Capture-MS), APOL2 (Affinity Capture-MS), APOL2 (Proximity Label-MS), APOL2 (Proximity Label-MS), BSG (Affinity Capture-MS), UBL4A (Affinity Capture-MS), FAM127A (Affinity Capture-MS), MAST3 (Affinity Capture-MS), APOL2 (Affinity Capture-MS), APOL2 (Affinity Capture-MS)

ESM2 similar proteins: A0A140LIF8, A0JN92, A7UHZ5, O08602, O08603, O08604, O14791, O15482, O77812, O95236, P01574, P01575, P01576, P01577, P01578, P05012, P59045, P70499, Q2KHK6, Q3B7D9, Q3TR54, Q3UQS2, Q56XQ0, Q5NCI0, Q5PPP4, Q5RFJ8, Q60766, Q6AYC2, Q6XZW6, Q6ZSC3, Q7TPX8, Q80ZF2, Q810Y8, Q86WN2, Q8BVM9, Q8CB12, Q8CCN1, Q8TCY9, Q99388, Q99J64

Diamond homologs: O14791, O95236, Q9BPW4, Q9BQE5, Q9BWW8, Q9BWW9, Q96LR9

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

97 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	76
Likely benign	8
Benign	1

Top pathogenic / likely-pathogenic (0)

SpliceAI

623 predictions. Top by Δscore:

Variant	Effect	Δscore
22:36231334:GCTTA:G	donor_loss	1.0000
22:36231335:CTTA:C	donor_loss	1.0000
22:36231336:TTAC:T	donor_loss	1.0000
22:36231337:TA:T	donor_loss	1.0000
22:36231338:A:AC	donor_gain	1.0000
22:36231339:C:CC	donor_gain	1.0000
22:36231463:CTCT:C	acceptor_gain	1.0000
22:36231465:CT:C	acceptor_gain	1.0000
22:36231471:T:TC	acceptor_gain	1.0000
22:36233241:CCT:C	acceptor_gain	1.0000
22:36239436:CTTA:C	donor_loss	1.0000
22:36239437:TTA:T	donor_loss	1.0000
22:36239438:TACCA:T	donor_loss	1.0000
22:36239439:A:AC	donor_gain	1.0000
22:36239439:ACCAA:A	donor_loss	1.0000
22:36239440:C:A	donor_loss	1.0000
22:36239440:C:CC	donor_gain	1.0000
22:36239451:T:TA	donor_gain	1.0000
22:36228276:CATCC:C	acceptor_gain	0.9900
22:36228278:TCCCT:T	acceptor_loss	0.9900
22:36228279:CC:C	acceptor_gain	0.9900
22:36228280:CC:C	acceptor_gain	0.9900
22:36228281:C:CC	acceptor_gain	0.9900
22:36228281:CT:C	acceptor_loss	0.9900
22:36228282:T:A	acceptor_loss	0.9900
22:36231339:CCT:C	donor_gain	0.9900
22:36231467:C:CC	acceptor_gain	0.9900
22:36231467:CTA:C	acceptor_loss	0.9900
22:36231471:T:C	acceptor_gain	0.9900
22:36233147:GCCTA:G	donor_loss	0.9900

AlphaMissense

2199 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
22:36228163:A:C	F85L	0.973
22:36228163:A:T	F85L	0.973
22:36228165:A:G	F85L	0.973
22:36231374:A:G	W35R	0.967
22:36231374:A:T	W35R	0.967
22:36231372:C:A	W35C	0.965
22:36231372:C:G	W35C	0.965
22:36227478:C:G	A314P	0.941
22:36228175:A:C	F81L	0.934
22:36228175:A:T	F81L	0.934
22:36228177:A:G	F81L	0.934
22:36231373:C:G	W35S	0.926
22:36231353:C:G	A42P	0.920
22:36228176:A:G	F81S	0.911
22:36227525:A:G	L298S	0.908
22:36227489:A:G	L310P	0.905
22:36227456:A:G	L321P	0.904
22:36227983:A:C	S145R	0.904
22:36227983:A:T	S145R	0.904
22:36227985:T:G	S145R	0.904
22:36228111:C:G	A103P	0.904
22:36228050:A:T	V123D	0.903
22:36228143:A:G	L92P	0.903
22:36231363:G:C	F38L	0.901
22:36231363:G:T	F38L	0.901
22:36231364:A:G	F38S	0.901
22:36231365:A:G	F38L	0.901
22:36227468:A:G	L317P	0.899
22:36227447:A:G	L324P	0.896
22:36228164:A:G	F85S	0.896

dbSNP variants (sampled 300 via entrez): RS1000093192 (22:36232581 A>G), RS1000145457 (22:36230496 A>G), RS1000271114 (22:36238514 G>A), RS1000609678 (22:36227887 T>C), RS1000816631 (22:36232921 G>A,C), RS1000876793 (22:36237227 G>A), RS1001001929 (22:36231584 T>G), RS1001293 (22:36234903 C>T), RS1001294 (22:36234944 C>A,T), RS1001539314 (22:36227054 G>A,T), RS1001548718 (22:36232497 G>C,T), RS1001553409 (22:36233454 T>A,C), RS1001720734 (22:36228412 GAATT>G), RS1001778799 (22:36238138 T>A,C), RS1001801906 (22:36238850 C>T)

Disease associations

OMIM: gene MIM:607252 | disease phenotypes:

GenCC curated gene-disease

Disease	Classification	Inheritance
schizophrenia	No Known Disease Relationship	Autosomal dominant

Mondo (1): schizophrenia (MONDO:0005090)

Orphanet (0):

HPO phenotypes

7 total (7 of 7 shown, HPO-id order):

HPO	Term
HP:0000006	Autosomal dominant inheritance
HP:0000738	Hallucinations
HP:0000746	Delusion
HP:0002353	EEG abnormality
HP:0007086	Social and occupational deterioration
HP:0100753	Schizophrenia
HP:0410291	Negativism

GWAS associations

2 associations (top):

Study	Trait	p-value
GCST008748_1	Epigenetic age acceleration in alcohol use disorder	5.000000e-08
GCST008748_7	Epigenetic age acceleration in alcohol use disorder	4.000000e-07

EFO canonical traits (2, from GWAS)

EFO ID	Trait name
EFO:0000473	epigenetic status
EFO:0022597	aging

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

47 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
sodium arsenite	affects cotreatment, increases abundance, increases expression	2
manganese chloride	affects cotreatment, increases abundance, increases expression	2
Manganese	increases expression, affects cotreatment, increases abundance	2
Nickel	increases expression	2
aristolochic acid I	increases expression	1
triphenyl phosphate	affects expression	1
bisphenol A	increases expression	1
pyrogallol 1,3-dimethyl ether	increases expression, affects cotreatment, affects localization	1
ethyl-p-hydroxybenzoate	decreases expression	1
trichostatin A	decreases expression	1
arsenite	affects binding, increases reaction	1
tris(1,3-dichloro-2-propyl)phosphate	decreases expression	1
cobaltous chloride	increases expression	1
nickel chloride	increases expression	1
perfluorooctanoic acid	decreases expression	1
potassium chromate(VI)	affects cotreatment, decreases expression	1
benazol P	affects expression	1
epigallocatechin gallate	affects cotreatment, decreases expression	1
perfluorooctane sulfonic acid	decreases expression	1
nutlin 3	affects cotreatment, increases expression	1
bisphenol B	increases expression	1
abrine	decreases expression	1
jinfukang	affects cotreatment, increases expression	1
bisphenol AF	increases expression	1
Resveratrol	affects cotreatment, increases expression	1
Leflunomide	decreases expression	1
Acetaminophen	decreases expression	1
Air Pollutants	increases abundance, increases expression	1
Arsenic	affects cotreatment, increases abundance, increases expression	1
Cannabinoids	increases expression	1

Cellosaurus cell lines

2 cell lines: 2 cancer cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_B1EJ	Abcam A-549 APOL2 KO 2	Cancer cell line	Male
CVCL_B2M2	Abcam A-549 APOL2 KO 1	Cancer cell line	Male

Clinical trials (associated diseases)

300 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00000374	PHASE4	COMPLETED	Treatment for First-Episode Schizophrenia
NCT00001656	PHASE4	COMPLETED	Comparison of Clozapine vs Olanzapine in Childhood-Onset Psychotic Disorders
NCT00007774	PHASE4	COMPLETED	To Determine if Olanzapine is More Cost Effective Than Haloperidol for the Treatment of Schizophrenia
NCT00014001	PHASE4	COMPLETED	CATIE- Schizophrenia Trial
NCT00018668	PHASE4	COMPLETED	Antipsychotic Response in Schizophrenia
NCT00034801	PHASE4	COMPLETED	Olanzapine Versus Active Comparator in the Treatment of Depression in Patients With Schizophrenia
NCT00034905	PHASE4	COMPLETED	A Comparison of Seroquel vs. Risperidone in Schizophrenia
NCT00036088	PHASE4	COMPLETED	Olanzapine Versus An Active Comparator in the Treatment of Schizophrenia
NCT00044187	PHASE4	COMPLETED	The Assessment of a Weight-Gain Agent for the Treatment of Olanzapine-Associated Anti-Obesity Agent in Patients With Schizophrenia, Schizophreniform Disorder, Schizoaffective Disorder, and Bipolar I Disorder
NCT00044655	PHASE4	COMPLETED	Switching Medication to Treat Schizophrenia
NCT00048828	PHASE4	COMPLETED	Treating Drug-Resistant Childhood Schizophrenia
NCT00053703	PHASE4	COMPLETED	Treatment of Early Onset Schizophrenia Spectrum Disorders (TEOSS)
NCT00056498	PHASE4	COMPLETED	Risperidone Treatment in Schizophrenia Patients Who Are Currently Taking Clozapine
NCT00061802	PHASE4	COMPLETED	Efficacy and Safety of Two Atypical Antipsychotics vs. Placebo in Patients With an Acute Exacerbation of Either Schizophrenia or Schizoaffective Disorder
NCT00080327	PHASE4	COMPLETED	Study of Three Doses of Aripiprazole in Patients With Acute Schizophrenia
NCT00088049	PHASE4	COMPLETED	Study of Olanzapine vs. Aripiprazole in the Treatment of Schizophrenia
NCT00090012	PHASE4	COMPLETED	Comparison of Continuing Olanzapine to Switching to Quetiapine in Overweight or Obese Patients With Schizophrenia and Schizoaffective Disorder
NCT00100776	PHASE4	COMPLETED	Efficacy of High Dose Olanzapine for the Treatment of Schizophrenia and Schizoaffective Disorder
NCT00103571	PHASE4	COMPLETED	Olanzapine Versus Aripiprazole in the Treatment of Acutely Ill Patients With Schizophrenia
NCT00108368	PHASE4	COMPLETED	The Effects of Risperidone and Olanzapine on Thinking
NCT00114595	PHASE4	COMPLETED	Ethyl-Eicosapentaenoic Acid and Tardive Dyskinesia
NCT00130923	PHASE4	COMPLETED	Risperidone Long-acting Versus Oral Risperidone in Patients With Schizophrenia and Alcohol Use Disorder
NCT00137020	PHASE4	COMPLETED	Clinical Effect Of Cross Titration Of Antipsychotics With Ziprasidone In Schizophrenia Or Schizoaffective Disorder
NCT00140166	PHASE4	COMPLETED	Treatment of Acute Schizophrenia With Vitamin Therapy
NCT00145847	PHASE4	COMPLETED	Naltrexone Treatment of Alcohol Abuse in Schizophrenia
NCT00148564	PHASE4	COMPLETED	Energy Homeostasis Under Treatment With Atypical Antipsychotics
NCT00156715	PHASE4	COMPLETED	Efficacy of Quetiapine in the Treatment of Patients With Schizophrenia and a Comorbid Substance Use Disorder
NCT00158223	PHASE4	COMPLETED	Effectiveness of Pimozide in Augmenting the Effects of Clozapine in the Treatment of Schizophrenia
NCT00159081	PHASE4	COMPLETED	One Year Drug Treatment in First-Episode Schizophrenia
NCT00159120	PHASE4	COMPLETED	Maintenance Treatment vs. Stepwise Drug Discontinuation in First-Episode Schizophrenia
NCT00159133	PHASE4	COMPLETED	Prodrome-Based Early Intervention With Antipsychotics vs. Benzodiazepines in First-Episode Schizophrenia
NCT00159757	PHASE4	TERMINATED	12 Week Open, Non-Comparative Switch Study Of Oral Ziprazidone In Previously Treated Schizophrenic Patients
NCT00167817	PHASE4	COMPLETED	Effect of Switch to Aripiprazole on Health and Smoking Parameters in Patients With Schizophrenia: A Pilot Study
NCT00169026	PHASE4	TERMINATED	Alcoholism and Schizophrenia: Effects of Clozapine
NCT00169039	PHASE4	TERMINATED	Clozapine Versus Chlorpromazine for Treatment-Unresponsive Schizophrenia
NCT00169065	PHASE4	COMPLETED	Effectiveness of Clozapine Versus Olanzapine for Treatment-resistant Schizophrenia
NCT00169091	PHASE4	TERMINATED	Clozapine Versus Haloperidol for Treating the First Episode of Schizophrenia
NCT00176423	PHASE4	COMPLETED	Efficacy Study of Galantamine for Cognitive Impairments in Schizophrenia
NCT00176436	PHASE4	COMPLETED	Atomoxetine for Treatment of Weight Gain in Olanzapine or Clozapine Patients
NCT00177008	PHASE4	COMPLETED	Aripiprazole for the Treatment of Schizophrenia With Co-Morbid Social Anxiety